Highest development stage: Phase 1

Development status: Inactive

Gram-positive activity

Gram-negative activity

Mechanism of Action/Target pathogen: Use against Enteric infections

Reason dropped: Catechol-containing compounds: MIC50s « 0.008-0.39 μg/mL against P. aeruginosa are superior to that of ceftazidime. These catecholic ,B-lactams were expected to show superior therapeutic responses against pseudomonal infections in humans, but they were discontinued due to side effects or unfavourable pharmokinetics in phase I/ II studies (2)